Huge opportunities remain for premium-priced tyrosine kinase inhibitors in PAH: Report

6 April 2016

The pulmonary arterial hypertension (PAH) space, which is currently burdened by significant unmet need, could benefit substantially from a class of drugs known as tyrosine kinase inhibitors (TKIs), which may aid development of a disease-modifying drug.

According to an analyst with research and consulting firm GlobalData, currently, there are 12 marketed therapies for the treatment of PAH from companies including Actelion (SIX: ATLN), GlaxoSmithKline (LSE: GSK), United Therapeutics, Bayer (BAYN: DE), Pfizer (NYSE: PFE), and Gilead Sciences (Nasdaq: GILD).

Lakshmi Dharmarajan, GlobalData’s senior analyst covering cardiovascular and metabolic disorders, says that manufacturing a drug using TKIs could present a significant opportunity for pharmaceutical companies, with the prospect of commanding a high premium over currently existing treatments, which already range in cost from $50,000-$150,000 per year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK